Genome-wide profiling identifies the genetic dependencies of cell death following EGFR inhibition
Porto, S. A.; Birdsall, G. A.; Harper, N. W.; Honeywell, M. E.; Lee, M. J.
Show abstract
EGFR is a proto-oncogene that is mutationally activated in a variety of cancers. Small molecule inhibitors targeting EGFR can be effective in slowing the progression of disease, and in some settings these drugs even cause dramatic tumor regression. However, responses to EGFR inhibitors are rarely durable, and the mechanisms contributing to response variation remain unclear. In particular, several distinct mechanisms have been proposed for how EGFR inhibition activates cell death, and a consensus has yet to emerge. In this study, we use functional genomics with specialized analyses to infer how genetic perturbations effect the drug-induced death rate. Our data clarify that inhibition of PI3K signaling drives the lethality of EGFR inhibition. Inhibition of other pathways downstream of EGFR, including the RAS-MAPK pathway, promote growth suppression, but not the lethal effects of EGFR inhibitors. Taken together, our study reveals the first "reference map" for the genome-wide genetic dependencies of lethality for EGFR inhibitors.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status 94%
- NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer 93%
- Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer 93%
Similar papers in this journal
- CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumors 94%
- Classical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer 93%
- Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug resistant gliomas 93%
Similar papers in this journal
- ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells 97%
- MDR1 Drug Efflux Pump Promotes Intrinsic and Acquired Resistance to PROTACs in Cancer Cells 94%
- Reporter-based screening identifies RAS-RAF stabilizing mutations as drivers of resistance to broad-spectrum RAS inhibition in colorectal cancer 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.